Glycostem donates funding to the Acute Leukemia Advocates Network and Leukaemia Care

11th May 2021 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, announced the donation to the Acute Leukemia Advocates Network (ALAN) and to Leukaemia Care. 

“We care for the health and well-being of blood cancer patients and their families.” said Troels Jordansen, CEO of Glycostem. “On top of our own efforts in developing and clinical testing our own NK cell therapy oNKord®, we are glad to support ALAN and Leukaemia Care. These donations also embrace part of our vision and mission, to cover the strong unmet medical needs of cancer patients and look after patients, staff and the environment.” 

The Acute Leukemia Advocates Network (ALAN) is an independent global network of patient organisations, dedicated to changing outcomes of patients with all types of acute leukemias by strengthening patient advocacy in that area. Leukaemia Care is a UK national blood cancer support charity, who are dedicated to ensuring that anyone affected by blood cancer receives the right information, advice and support.